27371349|t|A Cyclin D2 -derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
27371349|a|Protein degradation by the proteasome generates functional intracellular peptides. Pep5, a peptide derived from Cyclin D2, induces cell death in tumor cell lines and reduces the volume of rat C6 glioblastoma tumors in vivo. Here, we chose the human MDA-MB-231 breast cancer cells to evaluate the mechanism of cell death induced by pep5 in different phases of the cell cycle. Fluorescently labeled pep5, monitored by real time confocal microscopy, entered the MDA-MB-231 cells 3min after application and localized to the nucleus and cytoplasm. Pep5 - induced cell death was increased when the MDA-MB-231 cell population was arrested at the G1/S transition or in S phase compared to asynchronous cells. Pep5 induced permanent extracellular signal-regulated kinase (ERK1/2) phosphorylation in MDA-MB-231 cells synchronized in G1/S or S phase. Affinity chromatography followed by mass spectrometry identified CLIC1 and Plectin as the only two proteins that interacted with pep5 in both asynchronous and synchronized MDA-MB-231 cells. These interactions could explain the long-lasting ERK1/2 phosphorylation and the cytoskeleton perturbations in the MDA-MB-231 cells, in which the stress fibers ' integrity is affected by pep5 treatments. These data suggest that pep5 has potential therapeutic properties for treating specific types of cancers, such as breast cancer cells. Pep5, a natural intracellular peptide formed by the degradation of Cyclin D2 through the ubiquitin-proteasome system, induces cell death when reintroduced into MDA-MB-231 breast cancer cells, which express low levels of Cyclin D2, specifically in G1/S arrested cells or in cells that are passing through S phase. Under these conditions, pep5 is able to interact with different intracellular proteins, primarily cytoskeleton and proteasome components, which can lead to cellular apoptosis. Together, our data suggest that pep5 is an intracellular peptide with therapeutic potential for treating specific types of tumors with low expression of Cyclin D2 by inhibiting cell proliferation.
27371349	2	11	Cyclin D2	T103	UMLS:C2718191
27371349	21	28	peptide	T103	UMLS:C0030956
27371349	46	63	cell cycle phases	T038	UMLS:C1516337
27371349	78	84	ERK1/2	T103	UMLS:C0600388
27371349	88	103	cause the death	T033	UMLS:C0007465
27371349	107	126	breast cancer cells	T017	UMLS:C1512505
27371349	127	146	Protein degradation	T038	UMLS:C0597304
27371349	154	164	proteasome	T038	UMLS:C1752727
27371349	186	199	intracellular	T082	UMLS:C0178719
27371349	200	208	peptides	T103	UMLS:C0030956
27371349	210	214	Pep5	T103	UMLS:C0030956
27371349	218	225	peptide	T103	UMLS:C0030956
27371349	239	248	Cyclin D2	T103	UMLS:C2718191
27371349	258	268	cell death	T038	UMLS:C0007587
27371349	272	288	tumor cell lines	T017	UMLS:C0085983
27371349	315	318	rat	T204	UMLS:C0034693
27371349	319	341	C6 glioblastoma tumors	T038	UMLS:C0017636
27371349	342	349	in vivo	T082	UMLS:C1515655
27371349	370	386	human MDA-MB-231	T038	UMLS:C3898556
27371349	387	406	breast cancer cells	T017	UMLS:C1512505
27371349	410	418	evaluate	T058	UMLS:C0220825
27371349	423	446	mechanism of cell death	T038	UMLS:C1708951
27371349	458	462	pep5	T103	UMLS:C0030956
27371349	476	500	phases of the cell cycle	T038	UMLS:C1516337
27371349	502	523	Fluorescently labeled	T058	UMLS:C0079367
27371349	524	528	pep5	T103	UMLS:C0030956
27371349	543	572	real time confocal microscopy	T058	UMLS:C0242842
27371349	586	596	MDA-MB-231	T038	UMLS:C3898556
27371349	597	602	cells	T017	UMLS:C1512505
27371349	630	639	localized	T082	UMLS:C0392752
27371349	647	654	nucleus	T017	UMLS:C0007610
27371349	659	668	cytoplasm	T017	UMLS:C0010834
27371349	670	674	Pep5	T103	UMLS:C0030956
27371349	685	695	cell death	T038	UMLS:C0007587
27371349	719	729	MDA-MB-231	T038	UMLS:C3898556
27371349	730	745	cell population	T017	UMLS:C1512505
27371349	766	781	G1/S transition	T038	UMLS:C1517341
27371349	821	826	cells	T017	UMLS:C0007634
27371349	828	832	Pep5	T103	UMLS:C0030956
27371349	851	888	extracellular signal-regulated kinase	T103	UMLS:C0600388
27371349	890	896	ERK1/2	T103	UMLS:C0600388
27371349	898	913	phosphorylation	T038	UMLS:C0031715
27371349	917	927	MDA-MB-231	T038	UMLS:C3898556
27371349	928	933	cells	T017	UMLS:C1512505
27371349	950	954	G1/S	T038	UMLS:C1517341
27371349	967	990	Affinity chromatography	T058	UMLS:C0008551
27371349	1003	1020	mass spectrometry	T058	UMLS:C0037813
27371349	1032	1037	CLIC1	T103	UMLS:C1314856
27371349	1042	1049	Plectin	T103	UMLS:C0071277
27371349	1066	1074	proteins	T103	UMLS:C0033684
27371349	1096	1100	pep5	T103	UMLS:C0030956
27371349	1139	1149	MDA-MB-231	T038	UMLS:C3898556
27371349	1150	1155	cells	T017	UMLS:C1512505
27371349	1207	1213	ERK1/2	T103	UMLS:C0600388
27371349	1214	1229	phosphorylation	T038	UMLS:C0031715
27371349	1238	1250	cytoskeleton	T017	UMLS:C0010853
27371349	1272	1282	MDA-MB-231	T038	UMLS:C3898556
27371349	1283	1288	cells	T017	UMLS:C1512505
27371349	1303	1316	stress fibers	T017	UMLS:C0887904
27371349	1344	1348	pep5	T103	UMLS:C0030956
27371349	1349	1359	treatments	T058	UMLS:C0087111
27371349	1385	1389	pep5	T103	UMLS:C0030956
27371349	1431	1439	treating	T058	UMLS:C0087111
27371349	1458	1465	cancers	T038	UMLS:C0006826
27371349	1475	1494	breast cancer cells	T017	UMLS:C1512505
27371349	1496	1500	Pep5	T103	UMLS:C0030956
27371349	1512	1525	intracellular	T082	UMLS:C0178719
27371349	1526	1533	peptide	T103	UMLS:C0030956
27371349	1548	1572	degradation of Cyclin D2	T038	UMLS:C0597304
27371349	1585	1612	ubiquitin-proteasome system	T038	UMLS:C1523807
27371349	1622	1632	cell death	T038	UMLS:C0007587
27371349	1656	1666	MDA-MB-231	T038	UMLS:C3898556
27371349	1667	1686	breast cancer cells	T017	UMLS:C1512505
27371349	1716	1725	Cyclin D2	T103	UMLS:C2718191
27371349	1743	1747	G1/S	T038	UMLS:C1517341
27371349	1748	1762	arrested cells	T017	UMLS:C0007634
27371349	1769	1774	cells	T017	UMLS:C0007634
27371349	1833	1837	pep5	T103	UMLS:C0030956
27371349	1873	1886	intracellular	T082	UMLS:C0178719
27371349	1887	1895	proteins	T103	UMLS:C0033684
27371349	1907	1919	cytoskeleton	T017	UMLS:C0010853
27371349	1924	1945	proteasome components	T103	UMLS:C0208355
27371349	1965	1983	cellular apoptosis	T038	UMLS:C0162638
27371349	2017	2021	pep5	T103	UMLS:C0030956
27371349	2028	2041	intracellular	T082	UMLS:C0178719
27371349	2042	2049	peptide	T103	UMLS:C0030956
27371349	2081	2089	treating	T058	UMLS:C0087111
27371349	2108	2114	tumors	T038	UMLS:C0027651
27371349	2124	2134	expression	T038	UMLS:C1171362
27371349	2138	2147	Cyclin D2	T103	UMLS:C2718191
27371349	2162	2180	cell proliferation	T038	UMLS:C0596290